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cessation and recommended in clinical guidelines. Despite that smoking cessation assistance from
the general practitioner can be effective, dissemination of clinical practice guidelines and efforts
on upskilling has not lead to the routine provision of smoking cessation advice among general
practitioners. Intensive counselling from the practice nurse could contribute to better smoking
cessation rates in primary care. However, the effectiveness of intensive counselling froma practice
nurse versus usual care from a general practitioner in combination with varenicline is still
unknown.
Materials and methods: A pragmatic randomized controlled trial was conducted comparing:
(a) intensive individual counselling delivered by a practice nurse and (b) brief advice delivered by
a general practitioner; both groups received 12-weeks of open-label varenicline. A minimum of
272 adult daily smoking participants were recruited and treated in their routine primary care
setting. The primary outcome was defined as prolonged abstinence from weeks 9 to 26,
biochemically validated by exhaled carbonmonoxide. Datawas analysed blinded according to the
intention-to-treat principle and participants with missing data on their smoking status at follow-
up were counted as smokers. Secondary outcomes included: one-year prolonged abstinence,
short-term incremental cost-effectiveness, medication adherence, and baseline predictors of
successful smoking cessation.
Discussion: This trial is the first to provide scientific evidence on the effectiveness, cost-
effectiveness, and potential mechanisms of action of intensive practice nurse counsellingKeywords:
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trial and discusses the pragmatic and/or explanatory design aspects.
Trial Registration: Dutch Trial Register NTR3067.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Tobacco use is a prominent determinant of the global
burden of disease and responsible for 31% Disability Adjusted
Life Years (DALY) lost [1]. In the Netherlands, still one out of
four people are daily smokers [2]. Even though most smokers
would like to quit [3], the number of quit attempts and their
success rate is low [4]. Increase of smoking cessation can be
achieved by improving the efficacy and effectiveness of
smoking cessation treatments.
Primary care is in a strategic position to play an important
role in smoking cessation: it has a wide reach into the
population, it is easily accessible for smokers [5], it is a familiar
environment and there is access to professional and effective
help [6,7]. Smokers who are considered to be difficult to reach,
e.g., smokerswith a low social-economic status or psychological
illnesses; heavy smokers; and smokers from different ethnic
backgrounds, may be more easily reached in primary care. In
countries were the primary care system is well developed, such
as the Netherlands, around 80% of the smokers visit their
primary healthcare centre each year [2].
Smoking cessation treatments available in primary care
can be categorized into behavioural support and pharmaco-
logical aids. Behavioural support can be given within a
continuum of care, from less intensive and one-time support
(brief advice) to more intensive behavioural support with
multiple sessions (counselling). There is a strong dose–
response relationship between number of sessions, total
contact time, and abstinence showing that intensive
counselling increases the chance of a successful quit attempt
compared to less intensive support [8]. Effective pharmaco-
logical aids include nicotine replacement therapy (NRT),
antidepressants bupropion and nortriptyline, and the partial
nicotine receptor agonists varenicline and cytisine [9–11].
Varenicline had better quit rates in clinical trials compared
to bupropion and NRT [12–14]. Combining behavioural
support and pharmacotherapy is most promising and
recommended in clinical guidelines [8,15–17].
The availability and effectiveness of multiple smoking
cessation strategies from the general practitioner (GP) [6],
dissemination of clinical practice guidelines, and efforts on
upskilling, have not led to the routine provision of smoking
cessation advice among GPs [18–20]. A survey in Australia
found that GPs were very pessimistic about giving cessation
advice, and only half of the GPs would give such advice in an
ideal situation [20]. However, practice nurses (PNs), as an
alternative workforce in primary care, have recently been
introduced in the Netherlands with the aim to reduce the
workload of GPs. They are expected to improve the quality of
care by cost-effectively managing chronic illnesses and
performing health promotion tasks such as smoking cessation
[21]. Evidence for the effectiveness of PN smoking cessation
counselling is limited, but results are positive and suggest the
same effectiveness as the English Smoking Cessation Services
[22]. Since PNs have more time for counselling than GPs,intensive counselling by the PN can contribute to higher
smoking cessation rates in primary care.
Furthermore, a recent meta-analysis showed some evi-
dence that the combination treatment increases smoking
cessation success, but most studies used NRT [23]. Evidence
on the effectiveness of combining counselling and varenicline is
still limited and it could be that the effect of counselling is less
evident when using varenicline, or that the effectiveness of
varenicline is amplified by intensive counselling. Though,
recent trials show promising results in favour of the combina-
tion of counselling and varenicline [24–26]. For example,
when varenicline was combined with an intensive 240-
minute counselling program, more than half of the patients
was prolonged abstinent at 6 months of follow-up, which was
significantly better than the combination of placebo with the
same intensive counselling program (58.1% vs 26.4%, OR 3.87,
95% CI 2.11–7.11) [24]. Nonetheless,more support for the effect
of combining varenicline with intensive versus less intensive
counselling is needed.Moreover, reasons why the combination
of intensive counselling and pharmacotherapy is most success-
ful are still unknown. One of the underlying mechanisms to
this effect might be that counselling increases adherence
to medication, which finally leads to better quit rates [27].
Intensive counselling is also more expensive than brief advice
and therefore the cost-effectiveness should be considered.
Previous clinical trials were very explanatory using very strict
in- and exclusion criteria, which limits the external validity of
the outcomes. Also, most evidence on the effectiveness of
varenicline resulted from research in clinical settings and not in
real world primary care settings.
Therefore, there is a need for evaluating the effectiveness of
intensive counselling from a PN versus usual care from a GP to
provide healthcare professionals, policymakers, and insurance
companies with evidence on the value of counselling from the
PN and on the effectiveness of the combination treatment of
intensive counselling by a PN with varenicline. When the PN
is equally or more effective than the GP, smoking cessation
could be shifted from the GP to the PN in order to reduce
the workload of the GP and approach the preferences of the
patient.
2. Materials and methods
2.1. Objectives
The primary objective was to compare the effectiveness of
individual counselling by a PN combined with open-label
varenicline versus brief advice by a GP combined with open
label varenicline on biochemically validated prolonged absti-
nence from week 9 to week 26 after treatment initiation in
smokers in a Dutch primary care setting.
Secondary objectives were:
• to determine the prolonged abstinence rate from weeks 9 to
52;
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from weeks 9 to 52;
• to investigate adherence to varenicline and whether adher-
ence mediated the treatment effect of individual counselling
by a PN on prolonged abstinence from weeks 9 to 26;
• to explore which participant characteristics at baseline are
predictors of prolonged abstinence from weeks 9 to 26
(predictors independent of treatment assignment);
• to explore which participant subgroups are more likely
to respond to intensive counselling by a PN (predictors
dependent of treatment assignment).Fig. 1. Trial design. SGE = Eindhoven Corporation of Primary Health Care Centres2.2. Design and setting
The study was a pragmatic, parallel group, individually
randomized controlled trial evaluating two behavioural sup-
port programmes combined with open-label varenicline for
smoking cessation: usual care from a GP versus intensive
counselling from a PN. For an overview of the study design, see
Fig. 1.
The trial was conducted in the Eindhoven Corporation of
Primary Health Care Centres (SGE) [28], which is a network of
10 primary healthcare centres covering approximately 65,000, PN = practice nurse, GP = general practitioner, CO = carbon monoxide.
301C. van Rossem et al. / Contemporary Clinical Trials 41 (2015) 298–312patients in the Netherlands. In total 42 GPs and 13 PNs from
SGEwere actively involved in the recruitment and treatment of
the trial participants. The logistics, including baseline and
follow-up measurements, were covered by the research team
of Maastricht University.
2.3. Study population
The aim was to recruit a study population that was a
realistic reflection of smokers in primary care, since research
volunteers and active treatment seekers may be unrepresen-
tative for routine care [29,30]. Therefore, smokers who
normally consulted their GP were recruited and as few
exclusion criteria as possible were used. To recruit smokers
who were motivated to quit smoking or at least willing to talk
about smoking cessation within primary care, healthcare
providers (GPs and PNs) and practice assistants were informed
that smokers could be referred to the research teamand leaflets
entitled “Do you think about quitting?” were dispersed in the
waiting rooms of the healthcare centres. The leaflet first
discussed the benefits of smoking cessation, and then the trial
was explained, describing it as an opportunity for smokers to
quit. The costless prescription of pharmacotherapy was
mentioned but not emphasized, so that this was not likely to
be themain reason for participants to partake. The leafletswere
printed on simple blue paper with black ink to save costs.
Smokers aged 18 years or older and daily smokers at the time
of randomization were included. There was no minimum limit
for the number of cigarettes smoked per day. Many guidelines
use a limit of 10 cigarettes per day or more for offering
pharmacotherapy, mainly because pharmacological trials
usually excludes smokers who smoke less [8,15,16]. However,
it has been shown that the percentage “light” smokers
(i.e., smoking less than 10 cigarettes per day) has been
increasing over the last few years and currently constitutes of
29% of the smokers in the Netherlands [2]. Moreover, light
smokers frequently use smoking cessation aids (about one in
three) [31] and offering pharmacotherapy in this group of
smokers is effective [32]. Smokers with contra-indications for
the use of varenicline were excluded from the trial, as would
happen in daily practice. The individual GP decided whether or
not varenicline was prescribed to the individual participant.
2.4. Intervention: intensive counselling by a practice nurse
We decided to develop a context-specific treatment
protocol based on existing, evidence-based methods and a
pragmatic approach because: 1) there is no international
consensus about which evidence-based strategies or tech-
niques should be used, 2) interventions are often focused on
motivating the smokers to quit and not at supporting a quit
attempt, 3) the intervention used in Dutch primary care is too
long (180 min) [27] and gives no clear guidance what to do
each consultation, 4) not all evidence about effective behaviour
change strategies and techniques [33–35] has yet been
translated into current counselling protocols and 5) practice-
based experiences of healthcare providers and patients could
make a protocol more transferable to real-life conditions.
The intervention was developed through a combination
of a top-down and bottom-up approach. A top-down
approach means that the intervention is based on a well-formed theory or literature findings (evidence-based
approach), whereas a bottom-up approach means that
practical experience drives the intervention development
(pragmatic approach) [36]. A multidisciplinary advisory
group was formed, consisting of three patients (smoker,
ex-smoker, attempting ex-smoker) and three healthcare
professionals from SGE (GP, PN, social psychiatric PN), three
scientists and a policy maker from SGE. The goal was to
develop a counselling protocol based on best practice and
best evidence, which could be implemented as a small scale
quality improvement in routine care. Working with the
multidisciplinary team created a well-supported counselling
protocol and commitment from healthcare professionals to
engage in the trial.
2.4.1. Timing of counselling sessions
Participants from the intervention group were entitled to
receive a total of 120min of counselling. The protocol consisted
of three individual face-to-face sessions and seven telephone
sessions with a PN (see Table 1). We believed a 120 min
counselling protocol would be feasible to implement in
primary care and could be reimbursed by healthcare insurance
companies in the Netherlands in the future. Only a smoking
cessation intervention that is effective, feasible, and cost-
effective is likely to be adopted. The duration of the counselling
sessions varied between 5 and 30 min. We distinguished 4
phases in the counselling protocol: preparation phase (week
1), initial quitting phase (week 2), conscious quitting phase
(weeks 3–5), and the maintenance phase (weeks 6–52) (see
Table 1). The timing and duration of the sessionswere based on
relapse curves of aided and unaided quit attempts [12,13,37]
and efficacy of front-loaded therapy [38]. While the original
protocol included a first consultation with the GP for every
participant, also for participants in the PN group, the healthcare
providers within the multidisciplinary team decided to drop
this regulation for practical reasons. Despite evidence suggests
that treatment delivered by two types of clinicians (for
example a GP and a PN) might be more effective than
treatment delivered by only one type of clinician [39], the
healthcare providers from the multidisciplinary team did not
want to burden the GP with an extra consultation. Firstly,
because this consultationwas expected to be used solely for the
prescription of varenicline. Secondly, because current practice
also did not involve the GP for an extra consultation when the
patient was treated by the PN. Therefore, participants in the
intensive counselling group did not receive any assistance from
their GP for smoking cessation.
2.4.2. Effective elements of counselling protocol
Effects of behaviour change interventions vary with the
techniques used in the intervention [34,35]. The content of the
current intervention was based on six behaviour change
techniques, namely: (1) front-loaded therapy [38], (2) the use
of expired carbon monoxide (CO) feedback [34,40], (3) stimu-
lation of an ex-smoker identity [34,41,42], (4) stimulating
adherence to varenicline [43], (5) use of a fixed target quit day
[44,45], and (6) enhancing motivation and self-efficacy [34].
(1) Counselling was front-loaded which means that it
started one week prior to the quit attempt and was most
intensive in the first five weeks. (2) The use of CO feedback,
prior to the quit attempt and 4 weeks after quitting should
Table 1
Content and planning of the counselling protocol.
Day/week Consult Content of sessions Time
Week 1 FFC 1 ○ Quickly discuss smoking behaviour, motivation, barriers, reasons for quitting, previous quit attempts
○ Biomarker feedback (expired air carbon monoxide)
○ Explanation varenicline: mechanism of action, clinical efficacy, route of administration,
safety profile and relation between success and adherence
○ Preparation and planning target quit day:
∘ patient chooses if he/she want to quit in the morning of target quit day or after second consult
∘ preparation on “ex-smoker-identity”: abrupt and complete cessation according to the “not a puff rule”
∘ Explanation treatment program:
∘ treatment program of 13 weeks
∘ first 4 weeks most important, therefore weekly contact
30
Quit day (week 2) FFC2 ○ Evaluation use of varenicline
○ Strengthen motivation and self-efficacy
○ Reinforce, confirm and repeat ex-smoker-identity: “since today you are an ex-smoker”
15
3 days post quit day
(week 2)
TC 1 ○ First 8 days are the toughest with a peak on the third day. “If you have a difficult moment,
wait with smoking until I call you, then we will discuss it first.”
○ Evaluation medication adherence
○ Discuss withdrawal symptoms and strategies to handle
○ Strengthen motivation and self-efficacy
○ Reinforce, confirm and repeat ex-smoker-identity
10
Week 3 TC 2 ○ Evaluate medication adherence
○ Strengthen motivation and self-efficacy
○ Reinforce, confirm and repeat ex-smoker-identity
10
Week 4 TC 3 ○ Evaluate medication adherence
○ Strengthen motivation and self-efficacy
○ Reinforce, confirm and repeat ex-smoker-identity
10
Week 5 FFC 3 ○ Biomarker feedback: visibility of direct health effect of smoking cessation
○ Discuss withdrawal symptoms and strategies to handle
○ Emphasis on self-efficacy and ex-smoker identity
15
Week 7 TC 4 ○ Discuss/stimulate medication adherence.
○ Emphasis on self-efficacy and ex-smoker identity
10
Week 11 TC 5 ○ Evaluate quit attempt
○ Prepare quitting varenicline
○ Discuss/remind motivation to quit
○ Discuss/remind risky moments for relapse.
○ Emphasis on self-efficacy and ex-smoker identity
10
Week 13 TC 6 ○ Evaluate medication adherence 5
Week 52 TC 7 ○ Evaluate quit attempt 5
FFC = face-to-face consultation. TC = telephone consultation.
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smokers were directly confronted with their lung intoxication
and their risk on various diseases. After quitting, ex-smokers
could see that their risk was immediately reduced. (3) Smokers
were stimulated by the PN to adopt an ex-smoker identity by
repeatedly using this term. Thiswould help to remain abstinent
through neurolinguistic programming. (4) Good adherence to
varenicline doubles the quit rates, therefore adherence should
be an important aspect during counselling [43]. The PN
emphasized the need for good adherence and discussed factors
related to poor adherence, e.g., experiencing side-effects and
the conception that varenicline was not necessary anymore
[46]. (5) The second session was planned on a fixed target quit
date. The patient was allowed to choose prior to the
appointment whether to quit smoking in the morning or after
the second session. (6) The PN tried to strengthen the
motivation and self-efficacy during every contact with the
patient. They elaborated personal reasons to quit smoking from
the patient, asked about and referred to situations where
(prolonged) abstinencewas difficult but successful, used verbal
persuasion, and planned coping responses with the patient. An
extensive description of the effective elements can be found in
Table 1.2.4.3. Communication style
Communication style can have a substantial impact on
behaviour change [47]. Research on the style and quality of
counselling or the effect of counselling training on cessation is
scarce but increasing [48,49]. PNs participating in this trial were
previously trained in the use of Dutch smoking cessation
guidelines and Motivational Interviewing (MI). MI is a
counselling style whereby the knowledge and experiences
from the patient; eliciting and strengthening the intrinsic
motivation of the patient; and resolving ambivalence towards
change, play an important role. In contrast tomore paternalistic
and authoritarian counselling styles, the attitude with MI is
more collaborative and supportive [50]. Also elements from
cognitive behavioural therapy, e.g., elaborating cognitions and
emotions with smoking cessation, identifying and removing
environmental cues which trigger the urge to smokewere part
of the PNs counselling style in routine care [51].
The emphasis of the counselling style was on strengthening
motivation, self-efficacy, and enhancing a non-smoker-identity.
We assumed that the participating PNs were capable of:
1) adopting a supportive and encouraging attitude; 2) commu-
nicating in a caring and patient way; 3) encouraging partici-
pants to talk about the quitting process; 4) identifying events,
303C. van Rossem et al. / Contemporary Clinical Trials 41 (2015) 298–312internal states, or activities that increase the risk of relapse;
5) teaching problem-solving skills to cope with high-risk
situations for relapse; 6) identifying and challenging irrational
beliefs about smoking; 7) considering indications and contra-
indications of smoking cessation medication (in particular
varenicline); 8) creating realistic expectations of medication
effects and alleviating fears regarding side effects and depen-
dence potential;
2.4.4. Implementation and adoption of the intervention
The PNs only received a short, personal explanation of the
counselling protocol by the researcher of approximately 1 h, at
the beginning of the trial. During the trial there was no
monitoring to ensure adherence with the counselling protocol
and PNs were free to deviate from the protocol when they
believed this would benefit the participant. We were aware
that thiswas insufficient to implement and control all elements
of the counselling protocol perfectly. However, more instruc-
tion would have made the intervention more expensive and
less pragmatic, while a real-world effectiveness trial is of
substantial public health importance.
2.5. Control: brief general practitioner advice
The participants allocated to the control group received
usual care from their GP. Smoking cessation interventions less
than 3min in duration have shown to be effective compared to
no intervention (odds ratio (OR) 1.30, 95% CI 1.10–1.60) [8].
Even among smokers who were not motivated to quit at a
given time, 16% still made a quit attempt within six months
after brief cessation advice [52]. Furthermore, smokers who
received assistance in quitting from their GP were more
satisfied with their quit attempt than those who did not
[53,54]. Although some variations in practice exist, the control
intervention minimally consisted of general advice to quit and
a prescription for varenicline. Brief advice increases the chance
of a successful quit attempt compared to no advice (risk ratio
(RR) 1.66, 95% confidence interval (CI) 1.42–1.94) [6]. Regu-
larly, there was no quit date agreed and no follow-up visit
arranged, but participants were free to contact their GP in case
of questions or side-effects.
2.6. Choice for varenicline
The primary goal was to compare the effectiveness of two
different forms of behavioural support when combined with
pharmacotherapy. To eliminate one important source of
confounding, the use of medication had to be standardised.
Varenicline is a partial agonist and antagonist of the neuronal
α4β2 nicotinic acetylcholine receptor (nAChR), which is
believed to have the highest specificity for nicotine [55–58]
andwasmore effective than placebo for smoking cessation (RR
2.27, 95% CI 2.02–2.55) [11]. Varenicline is more effective in
reducing craving, withdrawal symptoms, and the reinforcing
effects of smoking compared to bupropion and NRT, and
generated better quit rates [12–14]. Varenicline has also shown
to be the only pharmacological treatment for smoking
cessation with proven long-term efficacy in smokers with
Chronic Obstructive Pulmonary Disease (COPD) [59]. Further-
more, patients appeared to have less difficulties with taking
varenicline, because this drug has been developed specificallyfor smoking cessation, in contrast to antidepressants as
bupropion and nortriptyline [60].
2.7. Use of varenicline
Participants from both the intervention and control group
received open-label varenicline to test its effectiveness under
real life conditions. Vareniclinewas prescribed during an initial
visit with the GP or PN in week 1. The use was initiated while
the participant was still smoking and the target quit date was
during the second week of treatment (see Table 1). The
prescribed dosage was the recommended dosage of 0.5 mg
once a day for days 1–3, 0.5 mg twice a day for days 4–7, and
then 1 mg twice a day until the end of treatment (week 12).
Nevertheless, healthcare professionals were free to deviate
from this schedule when they believed this would be more
appropriate for their participant. Therewas an interactiveweb-
based program that is usually offered alongside the prescrip-
tion of varenicline (www.liferewards.nl). Participants were
allowed to visit this website.
2.8. Outcomes
2.8.1. Primary outcome
The primary outcome was biochemically validated
prolonged abstinence from smoking from week 9 through
week 26 after treatment initiation. A “grace period” was used
from the target quit date in week 2 until week 9 (i.e., a period
immediately after the target quit date in which continued
smoking is not counted as a failure) [61]. A non-smoker was
defined as a participant with a self-reported prolonged non-
smoking status with a maximum of 5 cigarettes smoked after
the grace period, biochemically confirmed by exhaled CO in
weeks 9 and 26 with a piCO+ Smokerlyzer (Bedfont Scientific
Ltd) as defined in the Russell Standard [61]. A CO-level of
b10 ppm was used as a biomarker of abstinence [62].
Randomized participants who withdrew, were lost to follow-
up, or failed to provide CO measurements for validation were
classified as smokers.
2.8.2. Abstinence from weeks 9 to 52
The first secondary outcome was prolonged abstinence
from smoking from week 9 through week 52 after treatment
initiation. Successful one-year prolonged abstinence was
defined as a participant with a self-reported prolonged non-
smoking status, with a maximum 5 cigarettes smoked after the
grace period, biochemically confirmed by exhaled CO in weeks
9, 26, and 52 with a piCO+ Smokerlyzer (Bedfont Scientific
Ltd) as defined in the Russell Standard [61].
2.8.3. Short-term incremental cost-effectiveness
Economic evaluation studies aim to determine the costs and
effects associated with an intervention in order to compare
these results with other interventions or current practice [63]
and to inform health policy. Calculating the costs per quitter is
the primary method for economic evaluations in smoking
cessation research [64]. However, due to the pragmatic design
of the current study, a full cost-effectiveness analysis from a
societal perspective was not possible and therefore a stripped-
down procedure from a payer perspective was performed,
excluding offset and societal costs [65].
304 C. van Rossem et al. / Contemporary Clinical Trials 41 (2015) 298–312Since one-year follow-up is the preferred time horizon for
economic evaluations of smoking cessation interventions, the
secondary outcome was used as the measure of effectiveness:
biochemically validated prolonged abstinence from week 9 to
week 52. Costs were based on direct intervention expenses and
calculated from real resource use, accounting for professional
time (consultations with healthcare professionals were regis-
tered into the electronic medical system (EMS) of SGE), and
costs of varenicline (based on actual prescriptions from
pharmacy fill records). The costs per quitter were computed
for both groups and the short-term incremental cost-
effectiveness of the intervention group and the control group
in comparison to each other were expressed as costs per extra
quitter [65]. Evaluating the incremental cost-effectiveness ratio
(ICER) enables to determinewhich of the two treatments offers
most “value for money” in terms of enabling the largest
number of smokers to quit at the lowest possible costs.
2.8.4. Adherence to varenicline
Medication intake was measured using electronic monitor-
ing devices (Medication Event Monitoring System (MEMS®)).
Also data from pharmacy fill records and questionnaire data
were gathered. The starting dose for the first two weeks of
varenicline was dispensed in the original packaging of the
manufacturer (11 × 0.5mg, 14 × 1mg) by the pharmacy. From
week 3, varenicline was dispensed in MEMS® vials by the
pharmacy for a maximum of 4 weeks at a time. Participants
had to refill their vial at the pharmacy until week 12 of
treatment. The cap of these vials contained a microchip that
saved the day and time of every opening (≥3 s) by the
participant during the 10 weeks of medication provision in the
MEMS® vials. It should be noted that the MEMS® vials did not
prompt the participants to use their medication and partici-
pants were not stimulated by the research team to take the
varenicline. The MEMS® data were read from an interface
when the vial was returned to the pharmacy and transmitted
into a computer using Powerview software (AARDEX Ltd.).
If patients do not use varenicline as prescribed, they do not
benefit optimally from pharmacological support. Recently,
it has been shown that good varenicline intake (≥80% of
days taken)was strongly associatedwith smoking cessation (6-
month abstinence rate 52% versus 25%) [43]. Five outcome
measures were used to assess adherence to varenicline in the
current study: (1) daily adherence was the percentage of days
on which any dose of medication was taken, (2) taking
adherence was the percentage of prescribed doses taken,
(3) dosing adherence was the percentage of correctly dosed
days, (4) timing adherence was the percentage of inter-dose
intervals not exceeding 25% of the prescribed dosing interval
(12 h), and (5) persistence was the duration of medication
intake in days with a maximum drug holiday of 72 h.
2.8.5. Baseline predictors of quit success
Understanding the determinants of successful quitting is
important to improve smoking cessation interventions. Several
factors are known to predict whether a quit attempt is more or
less likely to succeed, such as age, educational level, social
gradient, nicotine dependence, number of cigaretess per day,
age of smoking inititation, number and duration of previous
quit attempts, intention to quit, confidence in succes in
quitting, the presence of depression and/or anxiety, and urgeto smoke [66–68]. The current trial included these and some
unexplored, potentially interesting determinants, such as locus
of control, type of smoker, and treatment preferences, which
could complement the current knowledge on predictors of quit
success.
2.8.6. Treatment response
Treatment response usually varies among individuals, and
accounting for thatvariability in clinical study populations can
be useful for translating clinical trial outcomes into recommen-
dations for a more tailored treatment selection in routine care.
In order to make responsible use of healthcare resources,
identifying individual characteristics that moderate success in
smoking cessation can help to match smokers with a strategy
that is more likely to help them quit. For example, strategies
could be tailored to personality traits [69], socio-demographic
differences [70], smoking behaviour [2], or to initial response
on treatment [71]. Unfortunately, few studies investigate
differential response to smoking cessation interventions. One
recent study from Rose et al. (2013) successfully adapted
pharmacological treatment according to initial response to pre-
cessation nicotine patch use, which rescued smokers from an
unsuccessful attempt [71]. The goal was to understand which
participant subgroups are more likely to respond to intensive
counselling from a PN.
2.9. Questionnaires
Questionnaires were sent at baseline (T0), at 9 weeks (T9),
12 weeks (T12), 26 weeks (T26) and 52 weeks (T52) (see
Fig. 1). The following information was collected from each
respondent: baseline demographic characteristics, self-reported
health, past- and current smoking behaviour, nicotine depen-
dence, smoking cessation treatment preferences, cigarette
withdrawal symptoms, smoking-related cognitions, mental
health, quality of life, life events, and therapeutic alliance. For a
complete overview of the content of all questionnaires see
Table 2. The questionnaires should be completed within
4 weeks after the targeted date.
2.10. Adverse events
Adverse (AEs) and serious adverse events (SAEs) reported
spontaneously by the subject during telephone follow-up or
observed by the researcher during CO-measurement were
recorded. In questionnaire T12, participants were actively
asked about the presence of adverse events. All possible
adverse events of varenicline were listed with the response
options “not at all”, “very minor”, “minor”, “reasonable/
moderate”, “strong”, or “very strong” (see Table 3). Question-
naire T12 (“Did you experienced any other side effects that are
not mentioned in the above questions?”) and T26 (“Did you
experienced side-effects after stopping varenicline or did any
side-effects worsened after stopping varenicline?”) also
contained open-ended questions regarding adverse events.
2.11. Sample size calculation
The calculation of the required sample sizewas based on the
difference in efficacy between the intervention and control
group. Because studies comparing usual care from the GP with
Table 2
Content of measurements per questionnaire.
Concepts T0 T9 T12 T26 T52
Demographic characteristics X
Weight X X X X X
Lifestyle (breakfast, coffee, alcohol) X
Morbidity X
Health X X
Smoking
Heaviness of Smoking Index (HSI) [72,73] X
Past and current smoking behaviour [74] X
Type of smoker X
Modiﬁed Cigarette Evaluation Questionnaire (mCEQ) [75] X X X X
Michigan Nicotine Reinforcement Questionnaire (MNRQ) [76] X X X X X
Modiﬁed Reasons for Smoking Scale (MRSS) [77] X
Quit smoking
Previous quit attempts [74] X
Smoking status [61] X X X X
Health perception
Health concerns [78] X
Risk perception [78] X
Self-exempting beliefs [78] X
Psychological constructs
Reasons For Quitting scale (RFQ) [79] X
Smoking Speciﬁc Locus of Control (SSLC) [80] X
Motivation to quit or maintain quitted X X X X X
Conﬁdence in successful quitting X X X X X
Self-efﬁcacy [74] X X X X X
Ex-smoker identity X X X X
Withdrawal and adverse effects
Minnesota Nicotine Withdrawal Scale (MNWS) [81–83] X X X X X
Urge to smoke [67] X X X X X
Adverse effects during use of varenicline X
Adverse effects after 6 months starting varenicline X
Treatment
Treatment preferences (GP versus practice nurse) X
Use of varenicline X X
Satisfaction with therapy X
Working Alliance Inventory Short-form (WAI-S) [84] X
Pharmacological treatment used other than varenicline X
Expectations regarding important success factors X
Expectations regarding varenicline [85,86] X
Mental health
Hospital Anxiety and Depression Scale (HADS) [87–89] X X X X X
Life events (emotional major events in a person's life) X
Harm reduction (using less or alternative sources of nicotine) X
T0 = questionnaire sent at baseline. T9 = questionnaire sent 9 weeks after starting varenicline. T12 = questionnaire sent 12 weeks after starting varenicline.
T26 = questionnaire sent 26 weeks after starting varenicline. T52 = questionnaire sent 26 weeks after starting varenicline.
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varenicline were unknown at the time of study planning, the
estimated quit rates derived from the results of previous
varenicline trials [12,13] and from one of our own smoking
cessation trials that combined individual counselling with
nortriptyline for smoking cessation [90]. The estimated quit
rates of the control group were based on the quit rates when
using varenicline only, since we expected that the assistance of
the GP would consist of solitary the prescription of varenicline
and would not add up to the effect of varenicline alone.
Prolonged abstinence rates from weeks 9 to 26 were expected
to be 35% in the intervention group and 20% in the control
group. With α = 0.05 (two-sided), at least 136 participants
needed to be included in each group to detect a clinically
meaningful difference of 15% between the groups with an 80%chance. The total number of participants in the two groups
should therefore be 272.We did not add participants to correct
for any participants who were lost-to-follow up, because those
were regarded as smokers in the primary analysis. At this
moment, study recruitment has been closed earlier than
expected. In total, 295 participants were eligible for data
analysis.
2.12. Randomization
Eligible smokers were randomly assigned in a 1:1 ratio to
either the intervention group or control group by the use of a
computer determined sequence, within an interactive web
response system. After the patientwas included in the trial, the
research team contacted the healthcare centre, and the
Table 3
Adverse events of varenicline examined in questionnaire T12.
Headache Infection or inﬂammation of the airways
Dizziness Weight gain
Increased fatigue Increased appetite
Tensed muscles Weight loss
Muscle twitching Decreased appetite
Stiffness Increased thirst
Muscle spasms Dyspnoea
Paralysis Cough
Chest pain Sore throat
High blood pressure Post nasal drip
Rash Eye pain
Acne Tinnitus
Sexual dysfunction Difﬁculties falling asleep
Fever Abnormal dreams
Nausea Insomnia
Vomiting Restlessness
Diarrhoea Anxiety
Stomach ache Panic reactions
Constipation Depression
General discomfort Suicidal thoughts
Hoarseness
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telephone call. The health care centre contacted the patient to
make an appointment with the healthcare professional of the
group in which the patient was allocated. The member of the
research team who was mostly involved with the randomiza-
tion performed no CO-measurements and was not involved in
data analysis. Randomization was stratified for healthcare
centre, using a 6-block randomization scheme, to ensure a
similar distribution of group intervention and control group
among healthcare centres. No prognostic factors were used for
balancing.
When two persons from the same family or close friends
wanted to participate, theywere paired and randomized as one
cluster to the same group. This provided protection against
contamination across study groups. No more than two persons
per cluster were included in the trial.
Though the healthcare centre consisted of 10 locations, an
individually randomized trial was chosen instead of a cluster
randomized trial. A cluster randomized trial introduces a
greater complexity in design, logistics, analysis and leads to a
greater required sample size to preserve statistical power [91],
since the area's in which the locations assumed dependence
among individuals from the same location. To prevent and
check for contamination, the participants were coded in their
Electronic Medical Record (EMR) as a participant in the trial so
that participants from theGP groupwould not be treated by the
PN during the 6-month follow-up for smoking cessation. This
was checked in the electronic database of SGE at the end of the
trial.
2.13. Blinding
Blinding of participants and healthcare professionals was
impossible due to the nature of the treatments. Outcome
assessment was blinded for the researchers whenever possible.
Researchers never directly asked about the treatment, disclo-
sure by the participant during telephone and face-to-face
contact was avoided as much as possible. Data analysis was
fully blinded to group label (i.e., the data analystwas unaware of
the meaning of the group labels) and participant identificationnumber (i.e., participants received a new, random identification
number during the analyses).
2.14. Statistical analysis
All tests were conducted with α = 0.05 (two-sided) and
confidence intervals were based on a 95% confidence level. All
analyses were performed with SPSS (version 21; SPSS Inc,
Chicago, Illinois).
2.14.1. Primary analysis
The primary analysis compared prolonged abstinence rates
from weeks 9 to 26 among the two groups, with successful
abstinence measured by the participants' self-reported
prolonged non-smoking status and confirmed by an exhaled
CO measurement below 10 ppm in weeks 9 and 26. All
randomized participants who received at least one dose of
vareniclinewere included in an intention-to-treat analysis [92].
Participants with missing measurements (either due to
intermittent missingness, dropout, or refusal to undergo a CO
testing)were coded as smokers. To get an overall impression of
the effectiveness, the proportion of abstinent participants was
calculated for each measurement occasion and presented as a
function of time for the two groups.
A multiple logistic regression model with a fixed effect for
treatment group and a categorical variable corresponding to
the healthcare centres was used to examine whether the
chance of prolonged abstinence from weeks 9 to 26 differed
significantly between the two groups (primary outcome
analysis). The centre factor was included in the model to
account for any absolute differences in success rates between
centres and because the randomization was stratified by this
variable [93,94]. An adjusted primary analyses was performed
to correct for several, a priori chosen potential confounders
measured at baseline: age, gender, socio-economic status,
nicotine dependence, urge to smoke, self-efficacy, duration of
longest quit attempt, depression, anxiety, share of smokers in
the social environment, and alcohol misuse [66–68].
2.14.2. Short-term incremental cost-effectiveness
Costs per quitter (CPQ) were calculated for the intervention
and control group, using the following formula: CPQ= (C × N)
/ Q, where C were the direct costs of the treatment per smoker,
N was the total number of participants randomized in the
group, andQwas the total number of participants that achieved
prolonged abstinence fromweek 9 to 52 [65]. Then an ICERwas
calculated using the cost of the intervention per quitter and
intervention efficacy in means of additional life years gained,
based on the direct method described by Stapleton and West
(2012) [65]. This method is a conservative, simple, and clear
way for estimating ICERs for several age groups. Estimates of
life years gained were taken from the longest epidemiological
study [95]. After discounting, the additional life years gained
were adjusted for lifetime cessation without the intervention
and relapse after final follow-up [65].
2.14.3. Adherence to varenicline
The association between treatment group and adherence
was investigated, as well as the association between adherence
and quit success. Reasons for non-adherence were compared
between the intervention and control group and predictors for
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varenicline was based on returned MEMS® vials, pharmacy fill
records and questionnaire data. For participants with missing
data, an appropriate strategy for handling missing data was
sought [96]. As compliance data are typically skewed, medica-
tion persistence and adherence were described by means,
medians, and interquartile ranges.
Daily adherence, taking adherence, dosing adherence and
timing adherence were compared across treatment groups by
multiple linear regression analysis. In case the data showed the
expected non-normal (skewed) distribution, the data was
transformed. The models were adjusted for the following
covariates: age, gender, educational level and heaviness of
smoking index. An ancillary logistic regression analysis was
performed after dichotomizing daily adherence into good
adherence as ≥80% of days taken. To understand whether
high intensity, individual counselling by a PN improves
smoking cessation rates through higher medication adherence,
a mediation analysis (a series of regression models) was
performed [97]. Persistence was assessed using a Cox propor-
tional hazard regression model to evaluate the risk of
discontinuation across treatment groups, controlling for the
same covariates as in the linear regression analysis. A Chi-
square test was used to compare the reasons for stopping
varenicline given by smokers and non-smokers with treatment
group as predictor variable.
2.14.4. Predictors of quitting success
The following potential predictors measured at baseline
were analysed in amultiple logistic regressionmodel, controlled
for treatment group: age (continuous), gender (dichotomous),
socio-economic status (categorical), nicotine dependence (con-
tinuous), urge to smoke (continuous), self-efficacy (continu-
ous), duration of longest quit attempt (continuous), the
presence of anxiety and/or depression (continuous), share of
smokers in the social environment (continuous), reinforcing
effects of smoking (measured with the Michigan nicotine
reinforcement questionnaire (MNRQ)) (2 domains, continu-
ous), and alcohol misuse (categorical). Also, psychological
functions of smoking (measured with the Modified Reasons of
Smoking Scale (MRSS)) (4 domains, continuous) and locus of
control (2 domains, continuous) were expected to predict
quitting success and were included in the model.
2.14.5. Treatment response
Even though multiple factors potentially relate to hetero-
geneity of treatment response, due to insufficient power for
the interaction test, the potential treat of multiple testing,
and clinical usefulness, only three dichotomous predictors
were explored [98]. These predictors were selected based on
previous literature and clinical usefulness. Educational level
(high vs. low), nicotine dependence (addicted vs. strongly
addicted) and preferred treatment (yes vs. no; indicating
whether the participant was assigned to the treatment s/he
favoured (GP or PN)) were analysed in a logistic regression
modelwith biochemically validatedprolonged abstinence from
weeks 9 to 26 as the outcome variable. Statistical significance
values were presented from the change in the log-likelihood
ratio on entering the interactions between the subgroup effects
and the treatment effect into the model.2.15. Time frame
Recruitment, inclusion and randomization of participants
was planned to start in November 2011 and intended to
continue for 18 months until April 2013. The lastmeasurement
of the primary outcome was expected in October 2013 and all
secondary outcomeswere expected to be collected in July 2014.
The analysis of data regarding the primary research question
was not initiated before the completion of follow-up and data
collection in the last participants.
2.16. Logistics
An electronic, web-based Research Logistics Management
System was used for data entry, review, and monitoring. The
system provided a solid base for managing the personal data of
the participants, as well as a randomization module for reliable
distribution of the participants. The advantages of web-based
data collection included the avoidance of an additional
transcription step, fewer missing data, and the immediate
availability of the data for cleaning and analysing. Electronic
questionnaires allowed for easier tailoring of questions based
on conditions and/or responses. Participants who were unable
or unwilling to use the internet to fill out the questionnaires
were provided with corresponding paper and pencil versions.
2.17. Ethical approval and trial registration
Ethical approval was obtained from the Medical Ethics
Committee of Maastricht Academic Hospital and Maastricht
University (NL30057.068.09/METC 09-03-075) and registered
in the Dutch Trial Register (NTR3067).
3. Discussion
High quality evidence of the effectiveness of smoking
cessation interventions is needed to inform health policy on
smoking cessation in primary care. Primary care is in a strategic
position to play an important role in smoking cessation [6,7]
and has developed guidelines which contain successful strat-
egies for smoking cessation [8,15–17]. According to these
guidelines, combining behavioural support and pharmacother-
apy is most successful. However, direct evidence on the
effectiveness of combining counselling and varenicline is
insufficient [24–26] and reasons for the combination being
most successful are still unknown. Previous clinical trials were
very explanatory and a real-life study directly investigating the
effectiveness of intensive counselling in combination with
vareniclinewas needed. Our primary objective was to compare
the effectiveness of individual counselling by a PN with open-
label varenicline versus brief advice by a GP with open-label
varenicline in smokers under real-life conditions in a primary
care setting in the Netherlands. Secondary objectives included
evaluating the cost-effectiveness and adherence to varenicline,
and were aimed at better understanding the added value of
intensive counselling.
This trial investigates the difference in effectiveness of brief
advice (i.e., usual care) from a GP versus intensive counselling
from a PN, and therefore not only considers a distinction
between two different intensities of behavioural support, but
also between two different types of healthcare providers.
Fig. 2. PRECIS wheel. A visual representation of the ten indicators of the PRECIS tool. Each spoke represents one of the indicators, with the inside of the spoke
representing a more explanatory judgement and the outside of the spoke representing a more pragmatic judgement.
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intensity of support (the number of contacts and the time
spent during the contacts) and success rate [39], but also that
behavioural smoking cessation interventions aremore effective
when delivered by a GP than when delivered by a non-
physician healthcare professional, such as a PN [39]. A recent
study confirmed that even brief cessation advice from a GP can
be powerful [52]; no such evidence is available for other
healthcare professionals. Conversely, literature suggests that in
the Netherlands only less than a quarter of all smokers who
consult their GP actually receive brief cessation advice [2].
Moreover, smokers prefer assistance from the PN since the GP
is very passive in smoking cessation, and a PNhasmore time for
assistance and for offering a more tailored approach [99,100].
We expected that usual care from the GP consisted of only a
single consultation wherein varenicline was prescribed and
that there was no guidance at all. Therefore, we supposed that
the effect of 120 min of counselling from the PN would
outweigh the effect of 10 min of counselling from the GP.
The main strength of this trial was the pragmatic design,
improving the generalizability of the results. However, certain
concessions to the real-life situation weremade to improve the
internal validity of the trial. To assess whether elements of the
trial could be identified as being more pragmatic or explana-
tory, we used the Pragmatic-Explanatory Continuum Indicator
Summary (PRECIS) tool [101]. In general, pragmatic trials
investigate whether the intervention works under usual
conditions, whereas explanatory trials look at the effectivenessunder ideal conditions [101]. The PRECIS tool provides a visual
representation over ten research domains and shows that the
current trial is largely pragmatic (see Fig. 2). Some decisions
made the trial less pragmatic (see Table 4). For example: the
primary outcome (domain 7), prolonged smoking cessation,
was measured using a telephonic questionnaire and if the
participant claimed to be a non-smoker an appointment for a
CO-measurement was made with the research team. It would
have been more pragmatic if the registration of self-reported
smoking status was handled by the health centres as they
would normally do. However, this would have led to bias since
PNs are probably more accurate in collecting smoking status
then GPs and the time of registering smoking status may differ
among participants. Furthermore, the smoking status needed
to be biochemically validated andmeasured in an identical way
in both research groups.
The trial had some potential limitations. The primary
outcome of smoking cessation trials is preferably measured
after 52 weeks of follow-up, but his would have required a
much larger sample size. Nonetheless, the prolonged absti-
nence rate from weeks 9 to 26, as in the current trial, is a good
approximation for the abstinence rate from weeks 9 to 52.
Furthermore, the use of intention-to-treat (ITT) is conservative,
however it needs to be mentioned that due to the pragmatic
design, there is a chance of post-randomization exclusion.
Potential participants were not physically seen by the research
team or healthcare professionals before randomization to
check their study eligibility. Therefore, it could happen that
Table 4
Explanation of the different domains of the Pragmatic-Explanatory Continuum Indicator Summary for scoring.
Domain 1: Participant eligibility
Participants who smoked, regardless of their motivation to stop smoking or responsiveness to previous treatment, could have participated in the trial. As few
as possible exclusion criteria were used. Participants had to be over 18 years and had no known contra-indications for the use of varenicline, which was
already routinely applied in primary care. Also participants had to be sufﬁciently proﬁcient in Dutch, which could lead to selection bias and exclude a group
of ethnic minorities in the Netherlands. However, no ﬁgures were known about how many of those ethnic minorities are not ﬂuent in Dutch, smoke and
seek treatment in primary care. Nonetheless, ethnic minorities are often part of more deprived socioeconomic groups. Previous studies showed that lower
educated patients were more likely to be smokers and smoked more cigarettes per day [102], and that deprived socioeconomic groups had the same or
higher initiation ratios, were just as likely to use pharmacological aids for quitting, but had lower quitting success compared with patient in higher
socioeconomic groups [70,102].
When patients wanted to participate in the trial, they had to contact a telephone number or send an e-mail to the research team. Then, before randomi-
zation, participants were obliged to ﬁll in the baseline questionnaire completely, which took about 30 min. This could have led to the inclusion of
participants who were more motivated to participate in research, but in practice, none of the participants stepped out because of the questionnaire.
Domain 2: Intervention condition: ﬂexibility
Though a new protocol was developed for the intensive counselling, the PNs were highly ﬂexible on how to apply the counselling. The protocol was used as
best-practice and best-evidence, but there was the possibility to give more or less sessions if needed.
Domain 3: Intervention condition: healthcare providers expertise
Similar to primary care practices elsewhere in the Netherlands, SGE employed PNs who were capable of delivering individual counselling to smokers. All
nurses were trained in giving smoking cessation assistance as this is mandated by health insurers to get reimbursement. This training consisted of at least
2 days of training and included information on the behavioural and physiological reasons for smoking, the stages of change, increasing motivation,
preparation and assistance on the target quit day, aftercare, possible withdrawal symptoms, pharmacological options and possible self-help materials. Most
PNs also did a short Motivational Interviewing course of at least one day. Though information about training of the average Dutch PN is unknown, we
believed the PNs from SGE were generalizable with PNs in the rest of the Netherlands.
The PNs were not additionally trained in the context of the trial. The PNs only received a short, personal explanation of the counselling protocol by the
researcher of approximately one hour, at the beginning of the trial. During the trial there was no monitoring to check for treatment ﬁdelity and ensure
adherence with the counselling protocol and PNs were free to deviate from the content and planning of the protocol when they believed this would beneﬁt
the participant. The PNs had been trained according to the Dutch guidelines for smoking cessation and had received training 2–3 years before the start of
the trial. Therefore we assumed that the PNs were capable of giving smoking cessation support at a level that can be considered representative for the
average PN in the Netherlands.
Domain 4: Control condition: ﬂexibility
GPs were asked to give care as usual and were free to organize the support as they wanted if no PN existed. GPs needed at least one face-to-face contact in
order to prescribe varenicline, which was already applied in routine care. By all means, referral to the PN was not allowed.
Domain 5: Control condition: healthcare providers expertise
GPs were not additionally trained in smoking cessation and gave smoking cessation assistance as usual. Although there are some variations in practice, usual
care typically consisted of general advice to quit (sometimes with setting a quit date) and a prescription for varenicline.
Domain 6: Follow-up intensity
Contact for follow-up, including a quick telephone call to verify the participants' smoking status, a questionnaire and possibly a carbon monoxide
measurement, took place at week 9, week 12, week 26 and week 52. Since the ﬁrst ﬁve weeks seemed most important in prolonged smoking cessation, the
participants did not have contact with the research team during this sensitive period. The ﬁrst contact was after 9 weeks, and during all contacts, the
researcher was not allowed to give any advice regarding smoking cessation or enter into a personal relationship with the participant.
Domain 7: Primary trial outcome
The primary outcome was prolonged smoking cessation, which was also a relevant outcome for participants and healthcare providers. Prolonged smoking
cessation was measured by combining self-report during a telephone call and a carbon monoxide measurement using a handheld monitor when the
participant claimed to be a non-smoker. These measurements were quick, convenient, quantitative, and did not require invasive procedures. However,
contact with the research team was necessary to obtain those data for both groups.
Domain 8: Participant compliance with the intervention (medication and treatment)
Participants' adherence to varenicline was monitored using electronic monitoring devices (Medication Event Monitoring System (MEMS®). Though
participants did not receive any feedback on how they took their medication and were told that the information was used to associate the time of intake
with adverse events, it is not unlikely that the use of such a system inﬂuenced participants' awareness to medication adherence.
Domain 9: Healthcare provider compliance with the intervention
There was no measurement of practitioner adherence to improve treatment outcomes. However, GPs and PNs were accounting for professional time by
registering the consultations into the electronic database. GPs registered one single or double consultation per session PNs registered a code which
represented the time spent on the consultation (5, 10, 15 and 30 min). Though the use of this code was implemented during the start of the trial, SGE
needed this information for own use as well.
Domain 10: Analysis of primary outcome
We used an intention-to-treat analysis. If participants were eligible for participating, ﬁlled in the baseline questionnaire and received at least one dose of
varenicline, they were accepted for analysis. The analysis included all participants in the group they were allocated, regardless of eligibility, compliance
with treatment, or adherence to varenicline. In other words, the analysis attempted to see whether the treatment worked under the usual conditions, with
all the noise inherent therein.
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randomization if they did not meet the eligibility criteria.
Another limitation was that only patients and healthcareprofessionals from SGE were included in the trial. However,
the participating health centres were assumed to be represen-
tative for other healthcare centres in theNetherlands regarding
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specially trained in supporting smoking cessation and the PNs
were not more trained then mandated by health insurers.
Therefore, the results of the trial should be generalizable for the
Dutch situation (see also domains 1, 3, and 5 in Table 4).
Furthermore, no methods to check for treatment fidelity were
incorporated in the protocol, which makes it difficult to
judge the content of the consultations between participants
and GP/PN. However, we believe that both types of healthcare
providers were competent in giving smoking cessation assis-
tance as one might expect from the training they had received.
Nonetheless, we did an alternative quantitative check on the
number of consultations and time spent on counselling in the
trial based on the registrations in the electronicmedical system
(EMS) for each participant.
In the future, it is likely that an important portion of smoking
cessation support will be delivered in primary care by GPs and
PNs. Evaluation of the effectiveness and cost-effectiveness of
both professions is essential to inform the discussion about how
to effectively structure smoking cessation in primary care.
Furthermore, empirical evidence to encourage a combination
treatment of behavioural therapy and varenicline is needed.
Therefore, the results of this trial will make an important
contribution to the knowledge on this subject. Additionally,
more research is desired in what mediates the mechanisms of
change in the intervention. Not only the quantity of counselling
seems important in improving quit rates, but also the quality of
counselling. Questions about what is good counselling and how
this influences quit success should be investigated in the future.
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